# Biofrontera Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Biofrontera Inc.).

## Overview

Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on commercializing dermatology products built around photodynamic therapy. Its core offering is Ameluz® together with the BF-RhodoLED® and RhodoLED®XL lamps, which are used to treat actinic keratoses, a precancerous skin condition. The company sells these licensed products directly to dermatology offices and group practices through a national commercial team. Biofrontera also relies on related-party support from Biofrontera AG for regulatory, pharmacovigilance, and other back-office functions tied to its licensed-product model.

## Products & services

• Ameluz® topical gel for photodynamic therapy
• BF-RhodoLED® lamp system
• RhodoLED®XL lamp system
• Direct commercial sales to dermatology practices
• Regulatory and pharmacovigilance support services

## Customers

Biofrontera sells primarily to dermatology offices and dermatology group practices that perform in-office photodynamic therapy. These customers buy Ameluz® and the RhodoLED lamp systems because the products are used together as a treatment platform for actinic keratoses. Demand is driven by physician adoption, prescription volume, and institutional purchasing decisions rather than consumer demand. The company also depends on clinical and regulatory stakeholders indirectly, because continued product use requires maintained approvals, physician confidence, and reimbursement-friendly treatment economics.

## Geography

Biofrontera is headquartered in the United States and generates revenue through its U.S. commercial organization. The company’s disclosed business model centers on direct sales to domestic dermatology practices, so the U.S. is the key market for both revenue and operating execution. Its product and regulatory support structure also depends on Biofrontera AG and related entities outside the U.S., particularly for regulatory and pharmacovigilance support. Because the company is small and cash constrained, geography matters mainly through U.S. commercial penetration and the ability to maintain cross-border support arrangements efficiently.

## Strategy

Biofrontera’s strategy is to expand licensed-product sales of Ameluz® and the RhodoLED lamp systems while improving operating efficiency. Management explicitly links growth to deeper relationships in the dermatology community and to broader adoption of photodynamic therapy in office-based care. The company is also focused on reducing overhead and leveraging information technology to support margin improvement, which is important because it has a limited cash base and ongoing operating losses. A major strategic issue is maintaining access to regulatory, pharmacovigilance, and other support services from Biofrontera AG while gradually assessing whether those functions can be internalized or sourced elsewhere.

## Risks

Biofrontera faces substantial going-concern and liquidity risk because management states current capital resources are not adequate to fund the business for twelve months. The company also depends on licensed products and related-party supply/support arrangements, so any disruption in approvals, manufacturing, transfer pricing, or service agreements could impair sales and operations. Demand is exposed to seasonality because lamp-based photodynamic therapy is performed more often in winter, which can create quarter-to-quarter volatility in revenue and operating results. More broadly, the business is exposed to dermatology market adoption risk, reimbursement and physician utilization trends, and the competitive pressure typical in specialty pharmaceutical commercialization.

## Accounting

Biofrontera’s reported revenue is driven by product sales recorded net of trade discounts, allowances, and government rebates, so gross-to-net deductions are an important analytical item. The company also has meaningful seasonality, with photodynamic therapy demand historically higher in the first and fourth quarters, which can distort comparisons across quarters. Cost of revenues includes third-party logistics and distribution costs, while related-party cost of revenues reflects purchases from Biofrontera Pharma and inventory adjustments for scrapped, expiring, or excess products. Investors should also watch judgment-heavy estimates such as contingent consideration, fair value measurements, valuation and impairment of intangible assets, and stock compensation, all of which can materially affect reported earnings and balance-sheet values.

---

*Last updated: 2026-08-11T04:46:23.809592+00:00*